Glossary entry (derived from question below)
English term or phrase:
bone-sparing
Polish translation:
zapobiegający zmniejszaniu masy kostnej
Added to glossary by
Nowicki (X)
Jun 19, 2004 12:34
20 yrs ago
7 viewers *
English term
bone-sparing
English to Polish
Medical
Medical: Pharmaceuticals
Recent studies have suggested that skin and upper gastrointestinal tract irritation produced by nitrogen-containing bisphosphonates (N-BPs) is mechanistically linked to the bone-sparing effects of these compounds.
Proposed translations
(Polish)
4 +1 | zapobiegający zmniejszaniu masy kostnej |
Jaroslaw Michalak
![]() |
4 -1 | effect of preserving bone mass or increasing its loss |
Ann Nosova
![]() |
Proposed translations
+1
19 hrs
Selected
zapobiegający zmniejszaniu masy kostnej
http://www.borgis.pl/czytelnia/nm_reumatologia/07.php
http://www.adamed.com.pl/produkty.asp?who=1&id=2&page=26&lan...
http://www.libramed.com.pl/wpg/NumeryArchiwalne/17/06.html
być może mogłoby być po prostu: "zapobiegający osteoporozie", ale nie jestem całkiem pewien (czy mogą być inne przyczyny z.m.k.)
http://www.adamed.com.pl/produkty.asp?who=1&id=2&page=26&lan...
http://www.libramed.com.pl/wpg/NumeryArchiwalne/17/06.html
być może mogłoby być po prostu: "zapobiegający osteoporozie", ale nie jestem całkiem pewien (czy mogą być inne przyczyny z.m.k.)
4 KudoZ points awarded for this answer.
Comment: "dziękuję"
-1
17 hrs
effect of preserving bone mass or increasing its loss
I hope you will translate it in Polish by yourself.
Sparing-1/frugal( thrifty);economical(avoiding waste)http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&d...
Bone-sparing properties of oral contraceptives. Department of Obstetrics and Gynecology, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA.
A review of the research literature on the effects of oral contraceptives (OCs) on bone mass suggests that premenopausal OC use may exert as beneficial an EFFECT on PRESERVING BONE MASS as hormone replacement therapy does on stabilizing bone mass loss in menopausal and postmenopausal women. Of the 12 studies reported in the literature, 9 found some positive correlation between these two variables in postmenopausal and/or premenopausal and perimenopausal women. The most significant increases in bone mineral density were recorded among women who had used OCs for more than 3 years. One study found that bone mineral density increased by 1% for each year of OC use. The three studies that failed to confirm any differences between OC users and nonusers in bone mineral density could be criticized methodologically for their focus on subjects with less than 5 years of pill use. Clinical studies have indicated that an OC containing 20-35 mcg/day of ethinyl estradiol in combination with the progestin norethindrone produces the optimal BONE-SPARING EFFECT in premenopausal women while minimizing the risk of venous thrombosis. Since osteoporosis affects close to 20 million women and results in over 1 million bone fractures each year, this is yet another noncontraceptive benefit of OC use.
The problem is that this drug(s) is good from the one point of view (bone-sparing effect) but probably has the adverse effects ( skin and upper gastrointestinal tract irritation).And recent studies have suggested that there are just two sides of body's response, they aren't linked firmly.
Sparing-1/frugal( thrifty);economical(avoiding waste)http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&d...
Bone-sparing properties of oral contraceptives. Department of Obstetrics and Gynecology, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA.
A review of the research literature on the effects of oral contraceptives (OCs) on bone mass suggests that premenopausal OC use may exert as beneficial an EFFECT on PRESERVING BONE MASS as hormone replacement therapy does on stabilizing bone mass loss in menopausal and postmenopausal women. Of the 12 studies reported in the literature, 9 found some positive correlation between these two variables in postmenopausal and/or premenopausal and perimenopausal women. The most significant increases in bone mineral density were recorded among women who had used OCs for more than 3 years. One study found that bone mineral density increased by 1% for each year of OC use. The three studies that failed to confirm any differences between OC users and nonusers in bone mineral density could be criticized methodologically for their focus on subjects with less than 5 years of pill use. Clinical studies have indicated that an OC containing 20-35 mcg/day of ethinyl estradiol in combination with the progestin norethindrone produces the optimal BONE-SPARING EFFECT in premenopausal women while minimizing the risk of venous thrombosis. Since osteoporosis affects close to 20 million women and results in over 1 million bone fractures each year, this is yet another noncontraceptive benefit of OC use.
The problem is that this drug(s) is good from the one point of view (bone-sparing effect) but probably has the adverse effects ( skin and upper gastrointestinal tract irritation).And recent studies have suggested that there are just two sides of body's response, they aren't linked firmly.
Peer comment(s):
disagree |
Marcus Malabad
: the asker wants a Polish answer, please refrain from answering in En-Po questions!
19 hrs
|
what's your problem, I don't understand it, asker can say by himself
|
Something went wrong...